RS54899B1 - Jedinjenja tetrahidropirolotiazina - Google Patents

Jedinjenja tetrahidropirolotiazina

Info

Publication number
RS54899B1
RS54899B1 RS20160505A RSP20160505A RS54899B1 RS 54899 B1 RS54899 B1 RS 54899B1 RS 20160505 A RS20160505 A RS 20160505A RS P20160505 A RSP20160505 A RS P20160505A RS 54899 B1 RS54899 B1 RS 54899B1
Authority
RS
Serbia
Prior art keywords
compounds
tetrahydropyrrolothiazine
tetrahydropyrrolothiazine compounds
group
ch2oh
Prior art date
Application number
RS20160505A
Other languages
English (en)
Inventor
James Peter Beck
Steven James Green
Jose Eduardo Lopez
Brian Michael Mathes
Dustin James Mergott
Warren Jaye Porter
Zoran Rankovic
Yuan Shi
Brian Morgan Watson
Jr Leonard Larry Winneroski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of RS54899B1 publication Critical patent/RS54899B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Jedinjenja Formule:Naznačeno time što je A izabran iz grupe koja se sastoji od:R1 je H ili F;R2 je H, -CH2OH, C1-C3 alkil,R3 je H, F ili CN;R4 je H, F; ili CN; iR5 je H, -CH3 ili -OCH3 grupa;ili njegova farmaceutski prihvatljiva so.Prijava sadrži još 14 patentnih zahteva.
RS20160505A 2012-04-03 2013-03-27 Jedinjenja tetrahidropirolotiazina RS54899B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261619460P 2012-04-03 2012-04-03
US201261700960P 2012-09-14 2012-09-14
US201361758798P 2013-01-31 2013-01-31
PCT/US2013/033959 WO2013151832A1 (en) 2012-04-03 2013-03-27 Tetrahydropyrrolothiazine compounds
EP13715556.0A EP2836495B1 (en) 2012-04-03 2013-03-27 Tetrahydropyrrolothiazine compounds

Publications (1)

Publication Number Publication Date
RS54899B1 true RS54899B1 (sr) 2016-10-31

Family

ID=48083661

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160505A RS54899B1 (sr) 2012-04-03 2013-03-27 Jedinjenja tetrahidropirolotiazina

Country Status (19)

Country Link
US (3) US8629270B2 (sr)
EP (1) EP2836495B1 (sr)
JP (1) JP6067099B2 (sr)
CN (1) CN104185635B (sr)
AR (1) AR090474A1 (sr)
CA (1) CA2866201C (sr)
CY (1) CY1117688T1 (sr)
DK (1) DK2836495T3 (sr)
ES (1) ES2584827T3 (sr)
HR (1) HRP20160674T1 (sr)
HU (1) HUE030097T2 (sr)
JO (1) JO3143B1 (sr)
ME (1) ME02404B (sr)
PL (1) PL2836495T3 (sr)
PT (1) PT2836495T (sr)
RS (1) RS54899B1 (sr)
SI (1) SI2836495T1 (sr)
TW (1) TWI572610B (sr)
WO (1) WO2013151832A1 (sr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711655C (en) 2008-01-18 2013-03-05 Eisai R&D Management Co., Ltd. Condensed aminodihydrothiazine derivative
EP2912041B1 (en) 2012-10-26 2016-12-14 Eli Lilly and Company Tetrahydropyrrolothiazine derivatives as bace inhibitors
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI684452B (zh) 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
TWI570127B (zh) 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
EP3497105A1 (en) * 2016-08-11 2019-06-19 Eli Lilly And Company Aminothiazines and their use as bace1 inhibitors
TWI726329B (zh) 2018-06-22 2021-05-01 美商美國禮來大藥廠 2,3-二氫呋喃并[2,3-b]吡啶化合物
CN111184725B (zh) * 2020-02-27 2020-12-01 慈溪市人民医院医疗健康集团(慈溪市人民医院) 一种防治脑梗塞的药物制剂及其制备方法
CN111675659B (zh) * 2020-06-16 2022-03-11 阿里生物新材料(常州)有限公司 一种(5-氟嘧啶-4-基)甲醇的合成方法
CN112263583B (zh) * 2020-11-23 2021-10-22 诸城市精神卫生中心 一种治疗帕金森疾病的药物及其制备方法
CN113666878A (zh) * 2021-08-27 2021-11-19 宁夏常晟药业有限公司 一种5-溴-2-氯嘧啶-4-羧酸甲酯的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332005B (en) 2005-06-14 2010-10-21 Schering Corp Aspartyl protease inhibitors
JP5383483B2 (ja) * 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
CA2711655C (en) * 2008-01-18 2013-03-05 Eisai R&D Management Co., Ltd. Condensed aminodihydrothiazine derivative
AU2009239535A1 (en) 2008-04-22 2009-10-29 Schering Corporation Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) * 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
US7964594B1 (en) * 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
US20120245155A1 (en) 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
US8598161B2 (en) 2011-05-24 2013-12-03 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
EP2751116B1 (en) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds

Also Published As

Publication number Publication date
JP2015512445A (ja) 2015-04-27
CN104185635A (zh) 2014-12-03
HRP20160674T1 (hr) 2016-07-15
ME02404B (me) 2016-09-20
US20140256933A1 (en) 2014-09-11
CY1117688T1 (el) 2017-05-17
EP2836495B1 (en) 2016-05-18
EP2836495A1 (en) 2015-02-18
HUE030097T2 (en) 2017-04-28
PT2836495T (pt) 2016-07-18
US8629270B2 (en) 2014-01-14
PL2836495T3 (pl) 2016-11-30
JP6067099B2 (ja) 2017-01-25
US20130261111A1 (en) 2013-10-03
US20140094454A1 (en) 2014-04-03
ES2584827T3 (es) 2016-09-29
WO2013151832A1 (en) 2013-10-10
AR090474A1 (es) 2014-11-12
TW201400491A (zh) 2014-01-01
CN104185635B (zh) 2016-03-09
JO3143B1 (ar) 2017-09-20
TWI572610B (zh) 2017-03-01
CA2866201C (en) 2016-09-20
SI2836495T1 (sl) 2016-06-30
DK2836495T3 (en) 2016-08-15
US8889856B2 (en) 2014-11-18
CA2866201A1 (en) 2013-10-10
US8772282B2 (en) 2014-07-08

Similar Documents

Publication Publication Date Title
RS54899B1 (sr) Jedinjenja tetrahidropirolotiazina
RS54730B1 (sr) Inhibitori beta sekretaze
RS54526B1 (sr) Upotreba derivata pirazolospiroketona kao inhibitora acetil-coa karboksilaze
RS53301B (sr) Jednjenja tioacetata, kompozicije i postupci korišćenja
RS54207B1 (sr) Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja
EA201700230A1 (ru) Определенные аминопиридины, композиции на их основе и способы их применения
RS52261B (sr) Amidofenoksi indazoli kao korisni inhibitori c-met-a
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
RS53843B1 (sr) Jedinjenja bis(fluoroalkil)-1,4-benzodiazepinona
BR112017006251A2 (pt) novos compostos
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
RS54492B1 (sr) Kinazni inhibitor koji reguliše signalni put apoptoze
MY180083A (en) Tetrahydropyrrolothiazine compounds
PE20151752A1 (es) Amidas heterociclicas como inhibidores de cinasas
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
CO6680699A2 (es) Derivados de amina para el control de plagas
RS54260B1 (sr) Derivati aminodihidrotiazina kao bace inhibitori za tretman alzheimerove bolesti
RS54369B1 (sr) Nova jedinjenja hinolina supstituisana kao inhibitori s-nitrosoglutathione reduktaze
IN2015MN00405A (sr)
EA201690911A1 (ru) Соединения диметилбензойной кислоты
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
EA201492255A1 (ru) Феноксиэтилпиперидиновые соединения